nevirapine has been researched along with Abnormalities, Congenital in 4 studies
Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.
nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Further, the addition of single-dose TDF to single-dose nevirapine (SD-NVP) during delivery following maternal ZDV use during pregnancy significantly reduces the frequency of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance." | 8.85 | Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: is it time to move on from zidovudine? ( Foster, C; Gibb, DM; Lyall, H; Olmscheid, B; Pearce, G; Zhang, S, 2009) |
| " However, zidovudine administered with lamivudine and indinavir was associated with increased risk of preterm births, zidovudine administered with nevirapine was associated with increased risk of stillbirths, and lamivudine administered with stavudine and efavirenz was associated with increased risk of low birth weight." | 4.98 | Comparative safety and effectiveness of perinatal antiretroviral therapies for HIV-infected women and their children: Systematic review and network meta-analysis including different study designs. ( Antony, J; Ashoor, HM; Blondal, E; Finkelstein, Y; Ghassemi, M; Gough, K; Hemmelgarn, BR; Hutton, B; Ivory, JD; Khan, PA; Lillie, E; Straus, SE; Tricco, AC; Vafaei, A; Veroniki, AA, 2018) |
| " Further, the addition of single-dose TDF to single-dose nevirapine (SD-NVP) during delivery following maternal ZDV use during pregnancy significantly reduces the frequency of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance." | 4.85 | Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: is it time to move on from zidovudine? ( Foster, C; Gibb, DM; Lyall, H; Olmscheid, B; Pearce, G; Zhang, S, 2009) |
| "Birth defects were evaluated among infants on the Pediatric AIDS Clinical Trials Group 316 trial that studied addition of peripartum nevirapine to established ARV regimen for prevention of mother-to-child transmission." | 2.76 | Birth defects among a cohort of infants born to HIV-infected women on antiretroviral medication. ( Culnane, M; Cunningham, CK; Delfraissy, JF; Huang, S; Kaiser, KA; Mandelbrot, L; Mofenson, L; Newell, ML; Scheuerle, A; Stanley, K; Watts, DH, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ogar, CK | 1 |
| Abiola, A | 1 |
| Yuah, D | 1 |
| Ibrahim, A | 1 |
| Oreagba, IA | 1 |
| Amadi, EC | 1 |
| Adeyeye, MC | 1 |
| Oshikoya, KA | 1 |
| Veroniki, AA | 1 |
| Antony, J | 1 |
| Straus, SE | 1 |
| Ashoor, HM | 1 |
| Finkelstein, Y | 1 |
| Khan, PA | 1 |
| Ghassemi, M | 1 |
| Blondal, E | 1 |
| Ivory, JD | 1 |
| Hutton, B | 1 |
| Gough, K | 1 |
| Hemmelgarn, BR | 1 |
| Lillie, E | 1 |
| Vafaei, A | 1 |
| Tricco, AC | 1 |
| Foster, C | 1 |
| Lyall, H | 1 |
| Olmscheid, B | 1 |
| Pearce, G | 1 |
| Zhang, S | 1 |
| Gibb, DM | 1 |
| Watts, DH | 1 |
| Huang, S | 1 |
| Culnane, M | 1 |
| Kaiser, KA | 1 |
| Scheuerle, A | 1 |
| Mofenson, L | 1 |
| Stanley, K | 1 |
| Newell, ML | 1 |
| Mandelbrot, L | 1 |
| Delfraissy, JF | 1 |
| Cunningham, CK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Maternal and Infant Monitoring for Evidence of Toxicity Related to Tenofovir Exposure: The Bone and Kidney Health Substudy of the IMPAACT 1077 PROMISE Protocol (Promoting Maternal and Infant Survival Everywhere)[NCT01066858] | 1,765 participants (Actual) | Observational | 2011-03-22 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for nevirapine and Abnormalities, Congenital
| Article | Year |
|---|---|
Comparative safety and effectiveness of perinatal antiretroviral therapies for HIV-infected women and their children: Systematic review and network meta-analysis including different study designs.
Topics: Abnormalities, Drug-Induced; Alkynes; Anti-HIV Agents; Benzoxazines; Child; Congenital Abnormalities | 2018 |
Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: is it time to move on from zidovudine?
Topics: Adenine; Adult; Africa South of the Sahara; Animals; Anti-HIV Agents; Antiretroviral Therapy, Highly | 2009 |
1 trial available for nevirapine and Abnormalities, Congenital
| Article | Year |
|---|---|
Birth defects among a cohort of infants born to HIV-infected women on antiretroviral medication.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Congenital Abnormalities; Double-Blind Method; Female; Heart | 2011 |
1 other study available for nevirapine and Abnormalities, Congenital
| Article | Year |
|---|---|
A Retrospective Review of Serious Adverse Drug Reaction Reports in the Nigerian VigiFlow Database from September 2004 to December 2016.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Anemia; Anti-HIV Agents; Anti-Retroviral Agent | 2019 |